Many different panels have been established for clinical research, in which the importance of tumor immune infiltrate densities, cell phenotypes, spatial localization, tertiary lymphoid structures, and the identification of targetable biomarkers for prognostic patterns, such as PD-L1, have been analyzed to study the effect of immunotherapy and potentially help to better match patients to appropriate treatment regimens (15, 46, 47). This evidence concerns the gene CD274 and neoplasm.